Last, the percentage of EGFR expression in the tumor cells was significantly associated with better OS in HNSCC patients receiving nimotuzumab in combination with CT [76], by contrast no association between EGFR expression and tumor outcome was observed in advanced HNSCC treated with nimotuzumab in combination with RT [77]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.